Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.5650 -0.0950 (-14.39%)
Streaming Delayed Price Updated: 3:22 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,050,066
Open 0.6700
Bid (Size) 0.5649 (22)
Ask (Size) 0.5650 (50)
Prev. Close 0.6600
Today's Range 0.5606 - 0.6700
52wk Range 0.3040 - 3.179
Shares Outstanding 145,337,046
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
8 Analysts Assess Sangamo Therapeutics: What You Need To Know
Via Benzinga
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'
U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading. 
Via Benzinga

Performance

YTD
-50.0%
-50.0%
1 Month
-38.6%
-38.6%
3 Month
-75.9%
-75.9%
6 Month
-34.8%
-34.8%
1 Year
-7.0%
-7.0%

More News

Read More
IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss
Via Stocktwits
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts
Via Benzinga
9 Analysts Have This To Say About Sangamo Therapeutics
Via Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For March 17, 2025
Via Benzinga
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
From Sangamo Therapeutics, Inc.
Via Business Wire
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
Via Benzinga
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
From Sangamo Therapeutics, Inc.
Via Business Wire
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks Lower Midday As 2024 Comes To An End
Via Talk Markets
Topics Stocks / Equities
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet
Via Benzinga
Exposures Fossil Fuels
US Stocks Open Higher; House Prices Increase In October
Via Benzinga
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Via Benzinga
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
Via Benzinga
Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
US Stocks Poised To Open Higher On Last Trading Day Of 2024: Analyst Sees S&P 500 At 7,000 In First Half Of 2025
Via Benzinga
Topics Stocks
Exposures US Equities
CompoSecure, Cemtrex And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga

Frequently Asked Questions

Is Sangamo Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sangamo Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sangamo Therapeutics, Inc. - Common Stock trade on?
Sangamo Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sangamo Therapeutics, Inc. - Common Stock?
The ticker symbol for Sangamo Therapeutics, Inc. - Common Stock is SGMO on the Nasdaq Stock Market
What is the current price of Sangamo Therapeutics, Inc. - Common Stock?
The current price of Sangamo Therapeutics, Inc. - Common Stock is 0.5650
When was Sangamo Therapeutics, Inc. - Common Stock last traded?
The last trade of Sangamo Therapeutics, Inc. - Common Stock was at 04/01/25 03:22 PM ET
What is the market capitalization of Sangamo Therapeutics, Inc. - Common Stock?
The market capitalization of Sangamo Therapeutics, Inc. - Common Stock is 82.12M
How many shares of Sangamo Therapeutics, Inc. - Common Stock are outstanding?
Sangamo Therapeutics, Inc. - Common Stock has 82M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.